Kramvis Andreas
Known title: DirectorCIK: 0001430870
Associated companies
Transaction History
| ATR | ▲ Buy | Grant | 1,266 | $0 | 5/3/2023 | View on chart |
| ATR | ▲ Buy | Grant | 1,302 | $0 | 5/4/2022 | View on chart |
| ATR | ▲ Buy | Grant | 1,266 | $0 | 5/3/2023 | View on chart |
| ATR | ▲ Buy | Grant | 1,302 | $0 | 5/4/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage
AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.